Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience has announced an upcoming earnings call on October 23, 2025, to discuss its third-quarter interim report. The call, led by CEO Søren Bregenholt and CFO Johan Giléus, will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company headquartered in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, an immuno-oncology approach that enhances T cell priming and counteracts the immunosuppressive tumor microenvironment. Their lead drug candidate, mitazalimab, is poised for Phase 3 development, having shown promising survival data in metastatic pancreatic cancer patients during Phase 2 trials.
Average Trading Volume: 502,045
Technical Sentiment Signal: Sell
Current Market Cap: SEK187.1M
For an in-depth examination of ATORX stock, go to TipRanks’ Overview page.